Cyclodextrins can solubilize poorly-soluble molecules for delivery in solution inhalers
There are several commercial pharmaceuticals with CyD-based formulations for parenteral use: but as far as it is known there aren’t yet any approved for inhalation delivery to treat diseases of the lung. To improve treatment of lung disease, CyDs can be used to solubilize poorly-soluble molecules for delivery in solution inhalers. Alternatively, these solutions can be spray dried to create particles for inhalation in dry powder inhalers (DPIs). However, the safety of CyD for inhalation would have to be demonstrated.